Clinical Trials

184 enrolled

Leukemia, Myeloid, Acute

NCT07437950 2026-03-19

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

126 enrolled

Leukemia, Myeloid, Acute

NCT06954987 2026-03-18

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

244 enrolled

Leukemia, Myeloid, Acute

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

70 enrolled

Leukemia, Myeloid, Acute

NCT07471841 2026-03-13

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

25 enrolled

Leukemia, Myeloid, Acute

NCT07463768 2026-03-11

MIVONU

60 enrolled

Leukemia, Myeloid, Acute

NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

112 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT07449286 2026-03-04

IFN-α in Relapse Prevention.

100 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05565105 2026-03-03

CD34+ Transplants for Leukemia and Lymphoma

LymphoidOther hematologic neoplasm

100 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07425782 2026-02-23

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

216 enrolled

Leukemia, Myeloid, Acute

NCT07423104 2026-02-20

A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia

24 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT07392970 2026-02-06

Motixafortide for MRD Sensitization in AML

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07214064 2025-10-09

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

Classical hematologyOther hematologic neoplasm

27 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT07025824 2025-09-03

RELEVANT

Classical hematologyOther hematologic neoplasm

220 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT07069933 2025-07-17

Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?

50 enrolled

Leukemia, Myeloid, Acute

NCT06900088 2025-03-28

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

20 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06667973 2025-03-12

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

80 enrolled

Disease, Leukemia, Myeloid, Acute

NCT06783478 2025-01-20

NKLMA

98 enrolled

Leukemia, Myeloid, Acute

NCT06754540 2025-01-17

Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.

51 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06765915 2025-01-09

Avapritinib Maintenance for AML With KIT Mutations

47 enrolled

Leukemia, Myeloid, Acute

NCT06598384 2024-10-01

VA as Maintenance Therapy Post Allo-HSCT in MDS and AML

40 enrolled

Leukemia, Myeloid, Acute

NCT06598969 2024-09-19

TMLI-MA

58 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06602323 2024-09-19

TMLI-RI

34 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06470841 2024-08-22

CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

85 enrolled

Leukemia, Myeloid, Acute

NCT06497062 2024-07-11

Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

47 enrolled

Leukemia, Myeloid, Acute

NCT05628623 2024-07-03

ERASE

184 enrolled

Leukemia, Myeloid, Acute

NCT06050941 2024-03-05

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

60 enrolled